Endocyte Chooses CEO Successor
Personalised therapy specialist Endocyte Inc. has appointed Mike Sherman president and CEO succeeding founding CEO Ron Ellis, who has resigned. Sherman has been the company’s chief financial officer since 2006, and took on the additional role of chief operating officer in 2014. Prior to this, he held a variety of executive roles, most recently as vice president of finance and strategic planning at Guidant Corporation.
You may also be interested in...
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
The big winners of the night were AstraZeneca and Roche as pharma, biotech and allied industries came together online on 2 December to celebrate during a ceremony hosted by Ed Balls.
SK set for Korean trial with vaccine, as Biological E begins human trials of Baylor vaccine. Meanwhile, DongWha gets a Phase II nod for potential drug, and Celltrion progesses with Phase II regdanvimab trial.